MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

Search

Akebia Therapeutics Inc

Chiusa

SettoreSettore sanitario

2.68 -1.47

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.67

Massimo

2.73

Metriche Chiave

By Trading Economics

Entrata

-5.9M

247K

Vendite

5.1M

62M

Margine di Profitto

0.395

Dipendenti

181

EBITDA

-6.1M

7.4M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+156.41% upside

Dividendi

By Dow Jones

Utili prossimi

6 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-162M

726M

Apertura precedente

4.15

Chiusura precedente

2.68

Notizie sul Sentiment di mercato

By Acuity

94%

6%

356 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Akebia Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

30 set 2025, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Eagers Automotive Enters Canada Via A$1 Billion Investment in CanadaOne Auto

30 set 2025, 23:43 UTC

Azioni calde

Stocks to Watch: GEO Group, Lithium Americas, Nike

30 set 2025, 23:12 UTC

Utili

Nike 1Q Sales Rise But Warns of Continued Weakness in China -- 2nd Update

30 set 2025, 22:48 UTC

Acquisizioni, Fusioni, Takeovers

Lifeway Foods, Danone Agree to Stay Litigation -- Update

30 set 2025, 22:01 UTC

Acquisizioni, Fusioni, Takeovers

Lifeway Foods, Danone Agree to Stay Litigation

30 set 2025, 21:17 UTC

Utili

Nike 1Q Sales Rise as Turnaround Progresses -- Update

30 set 2025, 20:47 UTC

Utili

Nike 1Q Sales Rise as Turnaround Progresses

30 set 2025, 23:45 UTC

Discorsi di Mercato

Nikkei May Trade in a Range Amid Uncertainty Over U.S. Govt Shutdown -- Market Talk

30 set 2025, 23:45 UTC

Discorsi di Mercato

Gold Edges Higher Amid Ongoing U.S. Government Shutdown Risks -- Market Talk

30 set 2025, 23:26 UTC

Acquisizioni, Fusioni, Takeovers

Eagers Automotive to Issue Shares at A$21.00 Each Via Entitlement Offer

30 set 2025, 23:26 UTC

Acquisizioni, Fusioni, Takeovers

Eagers Automotive to Launch Partly Underwritten A$452 Million Entitlement Offer

30 set 2025, 23:25 UTC

Acquisizioni, Fusioni, Takeovers

Eagers Automotive Says Equity Raising Includes A$50 Million Placement to Mitsubishi

30 set 2025, 23:24 UTC

Acquisizioni, Fusioni, Takeovers

Eagers Automotive Says Transaction With Mitsubishi Corp Worth A$70 Million

30 set 2025, 23:24 UTC

Acquisizioni, Fusioni, Takeovers

Eagers Automotive Says Mitsubishi Corp to Acquire 20% of easyauto123

30 set 2025, 22:54 UTC

Discorsi di Mercato

Timing of CSL's Change of CFO Queried by Bull -- Market Talk

30 set 2025, 22:38 UTC

Utili

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

30 set 2025, 22:32 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

30 set 2025, 22:32 UTC

Discorsi di Mercato

Commonwealth Bank Pushes Out Next RBA Rate Cut to February -- Market Talk

30 set 2025, 22:03 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

30 set 2025, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

30 set 2025, 21:02 UTC

Utili

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

30 set 2025, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

30 set 2025, 20:50 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

30 set 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

30 set 2025, 20:28 UTC

Utili

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Rises. -- Barrons.com

30 set 2025, 20:22 UTC

Utili

Nike 1Q North America Revenue $5.02B >NKE

30 set 2025, 20:22 UTC

Utili

Nike 1Q Asia Pacific & Latin America Revenue $1.49B >NKE

30 set 2025, 20:22 UTC

Utili

Nike 1Q Europe, Middle East & Africa Revenue $3.33B >NKE

30 set 2025, 20:22 UTC

Utili

Nike 1Q Greater China Revenue $1.51B >NKE

30 set 2025, 20:19 UTC

Utili

Nike Cash and Equivalents and Short-Term Investments Were $8.6 B as of Aug 31 >NKE

Confronto tra pari

Modifica del prezzo

Akebia Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

156.41% in crescita

Previsioni per 12 mesi

Media 7 USD  156.41%

Alto 8 USD

Basso 6 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Akebia Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

3

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

2.345 / N/ASupporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

356 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat